SNBIF (SanBio Co) Other Current Liabilities: $1.52 Mil (As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SNBIF SanBio Co Ltd SNBIF
22 GF Score
Price $16.45
! 1 Warning Sign
View Full Analysis

What is SanBio Co Other Current Liabilities?

SanBio Co SNBIF 22 Other Current Liabilities is $1.52 Mil as of Jan. 2026. GuruFocus rates SNBIF with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

SanBio Co's other current liabilities for the quarter that ended in Jan. 2026 was $1.52 Mil.

SanBio Co's quarterly other current liabilities increased from Jul. 2025 ($0.67 Mil) to Oct. 2025 ($0.75 Mil) and increased from Oct. 2025 ($0.75 Mil) to Jan. 2026 ($1.52 Mil).

SanBio Co's annual other current liabilities declined from Jan. 2024 ($3.44 Mil) to Jan. 2025 ($2.07 Mil) and declined from Jan. 2025 ($2.07 Mil) to Jan. 2026 ($1.52 Mil).

SanBio Co Other Current Liabilities Related Terms

SanBio Co Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for SanBio Co's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SanBio Co Other Current Liabilities Chart

SanBio Co Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24 Jan25 Jan26
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.25 3.76 3.44 2.07 1.52

SanBio Co Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.77 0.67 0.75 1.52 0.52
SNBIF
22GF Score
SanBio Co Ltd SNBIF
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SanBio Co Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $1.52 Mil mean?
SanBio Co (SNBIF) has a Other Current Liabilities of $1.52 Mil as of Jan. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on SanBio Co.
Is SanBio Co's Other Current Liabilities too high?
SanBio Co's current Other Current Liabilities is $1.52 Mil. Overall, SanBio Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does SanBio Co's Other Current Liabilities compare to VRTX and REGN?
SanBio Co's Other Current Liabilities of $1.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on SanBio Co. SanBio Co's current Other Current Liabilities is $1.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SanBio Co stock overvalued right now?
SanBio Co (SNBIF) has a current Other Current Liabilities of $1.52 Mil. The current Other Current Liabilities is $1.52 Mil. SanBio Co's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For SanBio Co (SNBIF), the current Other Current Liabilities is $1.52 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SanBio Co Business Description

Other Exchanges 4592:Japan
Address 8-1 Street Luke Tower 32nd Floor, Akashi-cho, Chuo-ku, Tokyo, JPN, 104-0044
SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.
22GF Score

Get the complete analysis for SNBIF

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.45
Price